TFX Stock Recent News

WAYNE, Pa., July 31, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) (the “Company”) today announced financial results for the second quarter ended June 29, 2025.

The global Chest Drainage Catheters Market, covering product types like thoracic and pleural drainage catheters and applications in cardiothoracic surgery and pneumothorax, is forecast to grow with a CAGR of 4.78% from 2025 to 2032. This expansion is driven by the increasing prevalence of chronic diseases and advances in minimally invasive procedures. North America is set to dominate the market due to robust healthcare infrastructure and high incidences of cancers requiring thoracic interventions. Key players include BD, Teleflex, and Cook. The global Chest Drainage Catheters Market, covering product types like thoracic and pleural drainage catheters and applications in cardiothoracic surgery and pneumothorax, is forecast to grow with a CAGR of 4.78% from 2025 to 2032. This expansion is driven by the increasing prevalence of chronic diseases and advances in minimally invasive procedures. North America is set to dominate the market due to robust healthcare infrastructure and high incide

Teleflex (TFX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

WAYNE, Pa., July 17, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its second quarter financial results and provide an operational update at 8:00 a.m. Eastern Time on Thursday, July 31, 2025.

TFX gains 2.9% after acquiring BIOTRONIK's vascular unit, boosting its cath lab presence and innovation pipeline.

WAYNE, Pa., July 01, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced that it has completed the previously announced acquisition of substantially all of the Vascular Intervention business of BIOTRONIK SE & Co. KG. The acquisition adds a broad portfolio of therapeutic products to Teleflex's portfolio of interventional access products, driving an enhanced global presence in the cath lab. The Vascular Intervention business will also establish Teleflex's global footprint in the fast-growing peripheral intervention market, and provide a channel for Teleflex products that currently have a peripheral indication.

WAYNE, Pa., June 12, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced findings from a new multinational study reporting efficacy of Arrow™ Chlorhexidine-Impregnated Central Venous Catheters (CVCs). This prospective cohort study included more than 6,670 patients from 12 Intensive care units in eight hospitals across India, Malaysia, Papua New Guinea, Colombia, Egypt and Turkey.

Timed with National Men's Health Month, the Prostate Monster ad campaign shines a light on quality-of-life issues associated with benign prostatic hyperplasia or BPH—a condition affecting millions of men 1 —and encourages them to take control of their health.

NEW YORK, May 22, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Teleflex Incorporated (NYSE: TFX) resulting from allegations that Teleflex may have issued materially misleading business information to the investing public.

NEW YORK CITY, NY / ACCESS Newswire / May 21, 2025 / WHY: New York, N.Y., May 21, 2025.